chevron_leftBack
As of 24 April 2025, Predictive Oncology Inc. has a market cap of $8.55M USD, ranking #33716 globally and #4767 in the United States. It ranks #3364 in the Healthcare sector, and #230 in the Medical Instruments & Supplies industry.
Key Stats
Market Cap
$8.55MUSD
Enterprise Value
$9.95MUSD
Revenue (TTM)
$1.62MUSD
EBITDA (TTM)
-$10.78MUSD
Net Income (TTM)
-$12.66MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Raymond Vennare
open_in_new
Employees
24
Founded
2002
Website
predictive-oncology.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 7.3% | 0.9% | -14% | -35% | 47% | -19% |
Upcoming Earnings
Earnings Date
Tue, May 13
Earnings Time
bedtime
After Close
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
POAI
Predictive Oncology Inc
ISIN: US74039M3097
Shares Out.:
Shares Outstanding:
8.932M1
Shares Float:
8.8M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.9573 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Predictive Oncology Inc.
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
